Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Core Insights - Kodiak Sciences Inc. has completed enrollment in its GLOW2 Phase 3 clinical trial for tarcocimab tedromer in patients with diabetic retinopathy, exceeding its target with over 250 patients [1][2] - The GLOW2 study is designed to evaluate the efficacy and safety of tarcocimab, with topline clinical data expected in the first quarter of 2026 [2][7] - Tarcocimab aims to address the treatment burden in diabetic retinopathy, with a dosing regimen of four doses in the first year and subsequent doses every six months [3][12] Company Overview - Kodiak Sciences is focused on developing transformative therapeutics for retinal diseases, utilizing its proprietary Antibody Biopolymer Conjugate (ABC) Platform [17][18] - The company is advancing multiple clinical programs, including GLOW2 for diabetic retinopathy and DAYBREAK for wet age-related macular degeneration (AMD) [18][19] Clinical Trial Details - The GLOW2 study is a randomized, double-masked, multi-center trial with a primary endpoint of improvement on the Diabetic Retinopathy Severity Scale (DRSS) [4][12] - Tarcocimab has shown promising results in previous studies, including GLOW1, where it achieved a 29-fold increased response rate in improving DRSS scores [13][14] Treatment Landscape - Current treatment options for diabetic retinopathy involve frequent injections, with fewer than 1% of patients receiving treatment due to the high burden [3][11] - Tarcocimab's potential for biannual dosing could significantly change the treatment landscape, helping millions of patients [3][11] Future Prospects - If GLOW2 is successful, Kodiak anticipates filing a regulatory package for tarcocimab that includes indications for diabetic retinopathy, wet AMD, and retinal vein occlusion [2][6] - The DAYBREAK study aims to broaden the efficacy profile of tarcocimab in wet AMD, with topline data expected in the second quarter of 2026 [2][9]